Trial Profile
Heart Rate Response to Regadenoson and Sudden Cardiac Death
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2022
Price :
$35
*
At a glance
- Drugs Regadenoson (Primary)
- Indications Cardiomyopathies; Coronary disorders; Left ventricular dysfunction; Myocardial infarction
- Focus Diagnostic use
- 12 Oct 2022 Status changed from active, no longer recruiting to completed.
- 11 Mar 2022 Planned End Date changed from 1 Dec 2021 to 1 Jun 2022.
- 04 Aug 2021 Planned End Date changed from 1 Jun 2021 to 1 Dec 2021.